152 related articles for article (PubMed ID: 11001367)
1. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles.
Murphy AM; Morris-Downes MM; Sheahan BJ; Atkins GJ
Gene Ther; 2000 Sep; 7(17):1477-82. PubMed ID: 11001367
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells.
Lee JS; Lee JH; Poo H; Kim MS; Lee SH; Sung MH; Kim CJ
Int J Oncol; 2006 Mar; 28(3):649-54. PubMed ID: 16465369
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
8. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T
Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811
[TBL] [Abstract][Full Text] [Related]
9. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.
Chikkanna-Gowda CP; Sheahan BJ; Fleeton MN; Atkins GJ
Gene Ther; 2005 Aug; 12(16):1253-63. PubMed ID: 15944731
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector.
Murphy AM; Sheahan BJ; Atkins GJ
Int J Cancer; 2001 Nov; 94(4):572-8. PubMed ID: 11745446
[TBL] [Abstract][Full Text] [Related]
11. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
12. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
13. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF.
Klimp AH; van der Vaart E; Lansink PO; Withoff S; de Vries EG; Scherphof GL; Wilschut J; Daemen T
Gene Ther; 2001 Feb; 8(4):300-7. PubMed ID: 11313804
[TBL] [Abstract][Full Text] [Related]
14. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors.
Dorange F; Piver E; Bru T; Collin C; Roingeard P; Pagès JC
J Gene Med; 2004 Sep; 6(9):1014-22. PubMed ID: 15352074
[TBL] [Abstract][Full Text] [Related]
16. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells.
Zhang J; Asselin-Paturel C; Bex F; Bernard J; Chehimi J; Willems F; Caignard A; Berglund P; Liljeström P; Burny A; Chouaib S
Gene Ther; 1997 Apr; 4(4):367-74. PubMed ID: 9176524
[TBL] [Abstract][Full Text] [Related]
17. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model.
Turturro F; Heineke HL; Drevyanko TF; Link CJ; Seth P
Gene Ther; 2000 Jun; 7(11):930-3. PubMed ID: 10849552
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
Zhu DE; Höti N; Song Z; Jin L; Wu Z; Wu Q; Wu M
Cancer Gene Ther; 2006 Aug; 13(8):762-70. PubMed ID: 16543917
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of recombinant alphaviruses as vectors in gene therapy.
Wahlfors JJ; Zullo SA; Loimas S; Nelson DM; Morgan RA
Gene Ther; 2000 Mar; 7(6):472-80. PubMed ID: 10757020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
